Effect of substitution on novel tricyclic HIV-1 integrase inhibitors

A series of novel tricyclic dihydropyrroloquinoline analogs was designed targeted at inhibition of HIV-1 integrase. Modification of R 2 and R 3 led to discovery of highly potent inhibitors of integrase. A series of novel tricyclic inhibitors of HIV-1 integrase enzyme was prepared. The effect of substitution at C-6 of the 9-hydroxy-6,7-dihydropyrrolo[3,4- g ]quinolin-8-one compounds was studied in vitro . Inhibitors with small side chains at C-6 were generally well tolerated by the enzyme, and the physicochemical properties of the inhibitors were improved by substitution of a small alkyl group at this position. A second series of analogs bearing a sulfamate at the C-5 position with various C-6 substituents were prepared to explore the interplay between the two groups. The SAR of the two classes are not parallel; modification at C-5 impacts the effect of substitutions at C-6.